``It was the perfect smokescreen. The rest of the sale of shares was a way for Orin and company to exit, through funds, that they control behind the scenes.`` ...this could be grounds for libel if not proven true. Under current law information that was wholly and patently false or that it was published "with reckless disregard of whether it was false or not" is libel.
...Uhave proof of L10 selling. Maybe he`s just like you...selling high and buying low. I have proof you plan to cover when the SP reaches a certain low. If the company was a complete bust why even cover, ride it into chapter 11
My take was a pumped rally only to be followed by a crash. However dble blinded data is now only being assessed by the company and results support an increased phase II cohort to have been recruited. I know your argument was why the increase #...must have been insignificant results, but contrary if they were good enough to plod forward with phase 2 a larger cohort can expedite phase3 given efficacy results. Not sure if SKS was bought as an in house team to help with the phase 3 testing but I wasn't thrilled with such a small employee based company like OHRP taking on a larger rivals in this space without required manpower and infrastructure. Phase 2 interim results are on schedule and only a delay in final results was announced from last QRT 2014 to 1ST QRT 2015. With the recruitment finally closed a month ago this delay reflecting 9months of trial time is perfectly understandable. The company may have thought SKS was a worthwhile endeavor and hence got the private financing to enable the acquisition.
It just may all come together in a viable result.
As to ORIN, I have yet to see an episode on American Greed featuring him. How does he get his money out via funds when the private placement netted the company $16 mil.
well we did hit $20 on no news....so $21's doable even on BS news.
If the MB is such a waste of anyone's time why r u here bashing 24/7. The SP has drifted down from $9.50 for only 2 days on very low volume from a previous pop. The stock is an easy target for trader's like yourself assured of a opportunity of a window period without news to short it. YOU HAVE NO IDEA IF THE DRUG WORKS OR NOT. Inside sellers have not dumped into the private equity, neither has institutional. Why would they hold so many shares if your premise is correct.
Like in Goldilocks, Liverwurst was much too hot, you are much too cold. She preferred it in the middle.
Crazy like a fox. Unfortunately FUD worked to scare enough retail away in order to solidify a bear raid takedown. Volume has all but vanished and with no news on the ST horizon this leaves SP a sitting duck vulnerable to a short attack.
...just putting the facts out there Opti...yesterday your guesstimate was 25%, today you're saying 10%...therefore you are guessing and making stuff up, trying to sound well researched. You have no clue.
If you're shorting this because you see a quiet period bfr. data is released so be it but based on conjectures about a pump & dump and non-efficacy is stretching the truth to serve your purpose of getting retail to sell.
FDA website for phase data interim results was always due in 2ND QRT June 2014...since I started checking it in Jauary this year. No change.
In case you haven't noticed some pessimistic bear clawed the pond's dam & let out all the water out. We need new rains to bring the level back up. Everyone left the pond, cept fur one lonely beaver and a high water mark.
"going into battle is like baking a cake. 1ST you need a battle plan"....Julia Childs
4. Well you got your wish Opti...down 7% on low volume sparce trades. A hedgefund's wet dream come true. Just sayin.
1. since when are phase 1 studies on animal groups no longer the norm?
2. one patient indicated 90% efficacy. Why couldn't this transfer to a much larger cohort. Proof of concept has been indicated,
3. you are speculating that was the reason behind the private financing. Only conjecture at this point.
4. SKS has a complete lab dept. working on eye disease...what better an addition to OHRP
5. Partnerships only happen when data is released, rarely bfr.
We could see another rally into June getting ready for 90% efficacy results. Confidence rally followed by partnership on much more favourable terms to OHRP after they show their stuff. They can afford to shop around with their financing. Not many shares out there left to short Opti. Better get working than just saying.
Thanx Irish...appreciate the update. I`m glad that John is doing so well. Scarlet should have had you present this at the last CC.
Always the best news on this board, deserving of a 21 Shamrock rating